DRREDDY Dr. Reddy's Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Dr. Reddy's delivered a milestone FY25 with record revenues and the first-ever $1 billion EBITDA achievement. The company demonstrated strong operational performance with significant growth in both revenue and profitability, supported by strategic acquisitions and continued investment in R&D capabilities across diverse therapeutic areas.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 5,015 | 5,563 |
| EBITDA | 1,192 | 1,443 |
| Net profit | 849 | 1,201 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
